137 related articles for article (PubMed ID: 37960733)
1. Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review.
Huang W; Liu Y; Li M; Xue Y; Bao W; Guo Y
Medicine (Baltimore); 2023 Nov; 102(45):e35946. PubMed ID: 37960733
[TBL] [Abstract][Full Text] [Related]
2. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
Ning P; Liu S; Cao H
J Med Case Rep; 2024 Jan; 18(1):51. PubMed ID: 38247005
[TBL] [Abstract][Full Text] [Related]
3. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
4. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
5. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
Huang X; Yang M; Wang L; Li L; Zhong X
Medicine (Baltimore); 2021 May; 100(19):e25795. PubMed ID: 34106616
[TBL] [Abstract][Full Text] [Related]
6. Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab.
Jouneghani NS; Phillip J; Dasanu CA
J Oncol Pharm Pract; 2022 Apr; 28(3):722-724. PubMed ID: 34791931
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
Popa LG; Giurcaneanu C; Portelli MG; Mihai MM; Beiu C; Orzan OA; Ion A; Anghel TH
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541099
[No Abstract] [Full Text] [Related]
9. [Immune Checkpoint Inhibitors Related Diabetes Mellitus:
A Report of 2 Cases and Literature Review].
Ren Y; Zhang L; Wang Y; Zhong D
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):61-65. PubMed ID: 35078286
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Hong AR; Yoon JH; Kim HK; Kang HC
Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
[TBL] [Abstract][Full Text] [Related]
11. Type 1 diabetes related to immune checkpoint inhibitors.
Tachibana M; Imagawa A
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101657. PubMed ID: 35450793
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics of immune checkpoint inhibitor-related type 1 diabetes mellitus].
Qiu JL; Luo SM; Yin WF; Li X; Zhou ZG
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(1):38-41. PubMed ID: 36594136
[TBL] [Abstract][Full Text] [Related]
13. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report.
Wen YP; Xiao HW; Yin JH; Guo HR; Shan MJ; Shen LP; Liu LS
Medicine (Baltimore); 2022 Dec; 101(48):e32076. PubMed ID: 36482651
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
Goff CB; Plaxe SC; White W; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1259-1263. PubMed ID: 36734125
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor-Induced Psoriasis: Diagnosis, Management, and a Review of Cases.
Pach JJ; Mbonu N; Bhullar S; Cohen JM; Leventhal JS
Dermatol Clin; 2024 Jul; 42(3):481-493. PubMed ID: 38796277
[TBL] [Abstract][Full Text] [Related]
17. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.
Luo J; Feng J; Liu C; Yang Z; Zhan D; Wu Y; Pan L; Zhang L
J Int Med Res; 2022 Sep; 50(9):3000605221121940. PubMed ID: 36171723
[TBL] [Abstract][Full Text] [Related]
18. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
19. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
20. Sintilimab-induced autoimmune diabetes: A case report and review of the literature.
Yang J; Wang Y; Tong XM
World J Clin Cases; 2022 Feb; 10(4):1263-1277. PubMed ID: 35211559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
